Back to search results

Molecular Profiling for Appendiceal Cancer

This study is looking at archived tumor tissue from people with appendiceal cancer or appendiceal adenocarcinoma. Researchers are using two tests, DNA Methylation Profiling and m6A Epitranscriptomic Profiling, to understand the cancer's molecular makeup. The goal is to find new ways to predict how the cancer might behave and to improve how doctors categorize the disease. This could help doctors better understand your specific cancer and guide treatment decisions. The study will measure how long people live (Overall Survival) and how long they live without the cancer getting worse (Progression-Free Survival) over about one year. The current status of the study is unclear.

Study design
This is an observational study, meaning researchers are looking at existing information rather than giving new treatments. It plans to include 400 participants.
What's involved
You would need to have archived tumor tissue available that is suitable for molecular profiling. You would also need to have relevant medical information available.
Compensation
Not stated in the trial record.
Follow-up
Participants' overall survival and progression-free survival will be measured through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07587268

Molecular Profiling for Risk Stratification in Appendiceal Cancer

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~400 participants
Updated 2026-06-29 on ClinicalTrials.gov
What's tested:DNA Methylation Profilingm6A Epitranscriptomic Profiling

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival
Measured over Through study completion, an average of 1 year
+1 more outcome measured

Conditions

Appendiceal Cancer
Appendiceal Adenocarcinoma

Explore related trials

Appendix Adenocarcinoma

Where it's being run

1 sites across 1 states
California1

Who to contact

Ajay Goel
[email protected]
6262184673
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.
Availability of archived tumor tissue suitable for molecular profiling.
Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.
Availability of relevant clinicopathologic data.
Availability of survival or follow-up information when applicable.
Age 18 years or older at diagnosis or tissue collection.

Exclusion

Insufficient tissue quantity or quality for molecular profiling.
Inadequate DNA or RNA quality for sequencing or molecular assay preparation.
Missing essential clinicopathologic information required for analysis.
Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site.
Patients who do not meet institutional review board or consent requirements, if applicable.

What this trial measures

  • Overall SurvivalThrough study completion, an average of 1 year

    Overall survival will be evaluated in relation to molecular profiling results and available clinicopathologic characteristics. Survival analyses may include Kaplan-Meier analysis and Cox proportional hazards models

  • Progression-Free SurvivalThrough study completion, an average of 1 year

    Progression-free survival will be evaluated in relation to molecular profiling results and available clinicopathologic characteristics. Time-to-event analyses may be performed using standard survival analysis methods.